FDA approves GE HealthCare's diagnostic drug for heart disease

The U.S. Food and Drug Administration approved GE HealthCare's (GEHC.O) diagnostic drug for use in detection of coronary artery disease, the company said on Friday.
Flyrcado, which is a radioactive diagnostic drug for positron emission tomography (PET) myocardial perfusion imaging (MPI), will be available in some U.S. markets in early 2025 before being expanded.